Novartis files Lescol/Lescol XL sNDAs
This article was originally published in Pharmaceutical Approvals Monthly
Novartis submits sNDAs for Lescol and Lescol XL (fluvastatin) for secondary prevention of cardiovascular events in patients who have undergone percutaneous coronary intervention (PCI) August 1, based on the four-year Lescol Intervention Prevention Study (LIPS). The study, published June 26 in the Journal of the American Medical Association, found that fluvastatin treatment in patients "with average cholesterol levels undergoing their first PCI significantly reduces the risk of major adverse cardiac events." Novartis is touting fluvastatin as the first statin to seek such an indicatio
You may also be interested in...
Two top officials in the US FDA’s device center are warning of delays in the agency’s review of submissions for new products that aren’t directly tied to the coronavirus pandemic.
With 12 new BTDs announced so far this year, 2021 is on pace to match the COVID-19-depressed total number of designations in 2020. Here’s a breakdown of the candidates that have received the designation.
Popular expedited review program results in a higher approval rate than the related fast track designation, but the COVID-19 era is seeing a drop in designations and a rise in complete response letters for BTD programs.